为什么今天捏住MNKD不放松？
老博今天发帖，好心劝告MNKD股票持有者暂时放弃，因为三重顶阻力巨大。言之有理！
然而，我仔细看了下目前的形势，决定暂时不动。原因如下：
1. K线图日线显示： MNKD上周五摆出旭日东升之上升态势。今天MNKD低开高走展示其上升动能之潜力。
2. 今天MNKD拉出上影线小阳线试探空方阻力。 期待明后天的大阳线上窜 。。。。。。
3. 只要本周大盘走高，本周MNKD多方就要上冲$11-$11.50 。。。。。。
MNKD过去半年日线10天均线走势图：
本帖只是表明个人看盘和操作决定。不是投资交易参考。
本人无意与任何人争论应当在MNKD何价位何时买进或卖出手中筹码。但是，我买进卖出都会及时告知。
股市交易有风险，高位跟风要谨慎！
买卖自断，盈亏与本帖无关！
为什么今天捏住MNKD不放松？
永远敬畏市场：试用K线技术分析探寻美股大盘走势
Always trade what you see, instead of what you think!
Always trade what you see, instead of what you think!
打印
被阅读次数
FirstInfo 发表评论于
Web Reference: http://seekingalpha.com/article/2270393-pricing-mannkind-corporation-the-sequel
MNKD Highest Price:
A Brief Review
As we saw last summer, the future held four possible paths for MannKind. The first, and shortest, had Afrezza failing to meet its objectives in clinical trials and MNKD stock dropping to penny stock status. The other three had the inhaled insulin product achieving success in the trials, leading to MannKind being acquired; securing a marketing partner; or deciding to commercialize on its own. As detailed in the two articles mentioned above, the takeover scenario suggested a 12-month buyout price of $27.50 a share; the partnership $28.00, and going it alone $27.42.
MNKD Highest Price:
A Brief Review
As we saw last summer, the future held four possible paths for MannKind. The first, and shortest, had Afrezza failing to meet its objectives in clinical trials and MNKD stock dropping to penny stock status. The other three had the inhaled insulin product achieving success in the trials, leading to MannKind being acquired; securing a marketing partner; or deciding to commercialize on its own. As detailed in the two articles mentioned above, the takeover scenario suggested a 12-month buyout price of $27.50 a share; the partnership $28.00, and going it alone $27.42.
FirstInfo 发表评论于
回复 'D&D' 的评论 :
不客气！
不客气！
D&D 发表评论于
谢谢专业分析！
登录后才可评论.
